Morgan Stanley
TTRX

Morgan Stanley’s Turn Therapeutics TTRX Stock Holding History

Morgan Stanley’s Portfolio TTRX Stock Details TTRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32K Hold
10,000
– – ﹤0.01% 6566
2025
Q4 		$39.4K Buy
+10,000
New +$41.7K ﹤0.01% 6500

Other funds holding TTRX

DI
DDFG Inc Thousand Oaks, California $464M AUM 16.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSC
Wellington Shields & Co New York $392M AUM 30.65% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
RW
RVW Wealth Los Angeles, California $1.52B AUM 23.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley's TTRX Position: Q1 2026 in Review

Morgan Stanley held its Turn Therapeutics (TTRX) position steady in Q1 2026 at 10,000 shares worth $32K. The position accounts for ﹤0.01% of the portfolio, ranked #6566.

Morgan Stanley first reported a position in TTRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $39.4K in Q4 2025. 20 funds tracked by Wall St. Rank hold TTRX as of Q1 2026.

  • Morgan Stanley held 10,000 shares of Turn Therapeutics worth $32K as of Q1 2026.
  • Morgan Stanley left its Turn Therapeutics share count unchanged in Q1 2026.
  • Turn Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6566 holding.
  • Morgan Stanley first reported a position in Turn Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Morgan Stanley's Turn Therapeutics position peaked at $39.4K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Turn Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.